Get startedLog in
    Picture of Arcus Biosciences logo

    RCUS — Arcus Biosciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapMomentum Trap
    All News

    Brief: Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response

    Picture of Arcus Biosciences logoArcus Biosciences
    01/06/2025 15:46
    June 1 (Reuters) - Arcus Biosciences Inc RCUS.N:

INITIAL DATA FROM THE ARC-20 STUDY OF CASDATIFAN PLUS CABOZANTINIB SHOWED NEARLY HALF OF PATIENTS WITH METASTATIC KIDNEY CANCER HAD A CONFIRMED RESPONSE

ARCUS BIOSCIENCES INC - ARC-20 STUDY SHOWS 46% RESPONSE RATE IN METASTATIC KIDNEY CANCER

Source text: ID:nBw2xJZfra

Further company coverage: RCUS.N

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Arcus Biosciences

    See all news